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Introduction: Antibodies against citrullinated peptides (anti-CCP) and increased levels of cytokines precede the
development of rheumatoid arthritis (RA) by several years. Recently, the proteins survivin and Fms-like tyrosine
kinase 3 ligand (Flt3L) have been identified as biomarkers of RA associated with joint destruction. Our objective
was to investigate the potential of survivin and Flt3L as predictors of RA in samples from patients prior to onset
of symptoms.
Methods: This study included 47 individuals sampled before onset of RA (median 2.5 years (IQR 4.5) and 155
matched controls, all were donors to the Medical Biobank of Northern Sweden, and 36 RA patients. Levels of
anti-CCP, survivin and Flt3L were measured using ELISAs and 29 cytokines/chemokines by multiplex detection.
Results: Levels of survivin were increased in pre-symptomatic individuals compared with controls (P = 0.003), whilst
the levels of Flt3L were similar. The frequency of survivin positivity in the pre-symptomatic individuals was increased
compared with the controls (36.2 vs.14.2%, P = 0.001) and predicted disease development (odds ratio (OR) =3.4
(95% confidence interval (CI) 1.6-7.2)). The frequency of survivin and Flt3L in RA patients was increased compared
with the controls (both, P <0.0001, OR = 12.1 (95% CI, 5.3-27.6) and OR = 11.0 (95% CI, 3.9-30.9), respectively).
Anti-CCP positive pre-symptomatic individuals and patients had significantly higher levels of survivin compared with
anti-CCP2 negative individuals. In pre-symptomatic individuals, survivin correlated with IL-12, IL-1β and IL-9 whereas
Flt3L correlated to a significantly broader spectrum of cytokines in RA patients.
Conclusion: Proto-oncogene survivin was increased in individuals prior to onset of symptoms of RA and was
correlated to cytokines suggesting its role at pre-clinical stages of the disease.Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by inflammation of joint synovial tissue
subsequently leading to the destruction of cartilage and
bone. RA is considered a multifactorial disease with both
genetic and environmental factors contributing to disease
development [1-3]. However, the aetiopathogenic factors
leading to disease development are not fully understood.
We, and others, have previously shown that anti-
citrullinated protein antibodies of several fine specific-
ities, as well as cytokines, can be detected several years
before onset of disease, suggestive of an upregulation of* Correspondence: solbritt.rantapaa.dahlqvist@medicin.umu.se
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reproduction in any medium, provided the orimmune system years before the onset of symptoms
indicating a joint disease [4-8].
The ability to predict the development of RA in non-
symptomatic individuals is as yet limited, and therefore
there is a need for additional biomarkers to be identified.
Survivin is an intracellular protein with anti-apoptotic
and cell-cycle regulatory functions, and Fms-like tyro-
sine kinase 3 ligand (Flt3L) is involved in the function of
cells of the immune system [9,10]. High levels of survi-
vin and Flt3L in blood and synovial fluid of patients with
RA are implicated in the pathogenesis of joint inflamma-
tion [11-13]. Flt3L has recently been highlighted within
a panel of preclinical biomarkers highly predictive for
the development of RA [8].
In the present study, using blood samples from the
Medical Biobank of Northern Sweden, we analyzed theral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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symptomatic individuals and matched controls together
with samples taken at the time of diagnosis. The results
were related to previously published concentrations of
cytokines and chemokines [5].
Methods
Subjects
A case–control study was conducted within the purview
of the Medical Biobank of Northern Sweden. The cohort
is population based and all adult residents in the county
of Västerbotten are continuously invited to participate.
Collection of the blood samples and the storage condi-
tions have previously been described in detail [6]. The
register of patients fulfilling the 1987 American Rheumatism
Association classification criteria for RA attending the
Department of Rheumatology and with a known date for
the onset of symptoms of joint disease was co-analyzed
with the register of the Medical Biobank [14]. Forty-seven
individuals were identified as being blood donors before
the onset of symptoms (14 men and 33 females; prepati-
ents), with a median predating (interquartile range) time
of 2.5 (4.5) years before symptom onset. Control subjects
were randomly selected from the same Medical Biobank
cohorts as the predisease individuals, and were matched
for sex and age at the time of blood sampling. A total of
155 control subjects (44 men and 111 women) were se-
lected. Of the individuals identified as prepatients, 36 had
also provided blood samples when attending the clinic at
the time of diagnosis, with a median (interquartile range)
time of 7.9 (5.2) months between onset of symptoms and
the time of diagnosis (Table 1). The Regional Ethics Com-
mittee at the University Hospital, Umeå, Sweden ap-
proved this study, and all participants gave their written
informed consent when donating samples.
Analysis of survivin and Flt3L concentrations
Survivin levels were measured in samples diluted 1:10
using a sandwich enzyme-linked immunoassay (ELISA)
and a pair of matched antibodies (DY647; R&D Systems,
Minneapolis, MN USA); the detection limit was set at 1




Median (interquartile range) age (years) 50.3 (18.7)
HLA-DR SEa, n (%) 28/47 (59.6)
Anti-CCP2 antibody-positive, n (%) 12/47 (25.5)
Anti-CCP, anti-cyclic citrullinated peptide antibodies; RA, rheumatoid arthritis. aShar
antigen-DRB1 0101/0401/0404/0405/0408.with an ELISA using a pair of matched antibodies (DY308;
R&D Systems), and a detection limit of 0.03 ng/ml. Cutoff
levels for both survivin and Flt3L had previously been de-
termined using samples from individuals with RA; samples
containing >450 pg/ml survivin or >130 pg/ml Flt3L were
considered positive [15].Analyses of anti-CCP antibodies and human leukocyte
antigen shared epitope
Detection of anti-cyclic citrullinated peptide antibodies
(anti-CCP) was performed using ELISAs according to
the manufacturer’s instructions (Euro-Diagnostica AB,
Malmö, Sweden). The cutoff value for positivity was set
at 25 AU/ml according to the manufacturer.
Human leukocyte antigen-DRB1 genotyping for the
0101/0401/0404/0405/0408 alleles was performed as de-
scribed previously [16].Analysis of cytokines, cytokine receptors and chemokines
The full methodology of cytokine analysis has been de-
scribed previously [5]; briefly, 29 cytokines and chemo-
kines were measured in plasma samples using multiplex
detection kits from Bio-Rad (Hercules, CA, USA). The
concentrations of interleukin (IL)-1β, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15,
IL-17, eotaxin (CCL11), IL-1 receptor antagonist, basic
fibroblast growth factor, granulocyte colony-stimulating
factor, granulocyte–macrophage colony-stimulating fac-
tor, interferon-gamma, interferon-inducible protein-10
(CXCL10), monocyte chemoattractant protein-1 (MCP-1/
CCL2), macrophage inflammatory protein-1α (CCL3),
macrophage inflammatory protein-1β (CCL4), platelet-
derived growth factor BB, tumor necrosis factor alpha,
vascular endothelial growth factor, monokine induced by
interferon-gamma (CXCL9), macrophage migration inhibi-
tory factor, and IL-2 receptor-alpha (CD25) in duplicate al-
iquots were analyzed with a Luminex 200 Labmap system
(Luminex, Austin, TX, USA) as described previously [5].
Data analysis was performed using Bio-Plex Manager soft-
ware version 4.1.1 (Bio-Rad). Standard curves were used to
extrapolate the cytokine/chemokine concentrations., rheumatoid arthritis patients and controls included in
als (n = 47) RA patients (n = 36) Controls (n = 155)
69.4 71.6
57.1 (7.6) 50.2 (17.1)
24/34 (70.6) 43/105 (41.0)
21/35 (60.0) 1/155 (0.6)
ed epitope defined as human leukocyte
Figure 2 Concentrations of survivin in presymptomatic
individuals and rheumatoid arthritis patients. A line indicates the
same individual.
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Continuous data were compared (prepatients vs. controls
or vs. patients) by nonparametric analyses using the
Kruskal–Wallis test for three groups and the Mann–
Whitney test for two groups. The Spearman rank cor-
relation test was used for correlation analyses. Logistic
regression analyses were performed to identify associa-
tions between proteins and anti-CCP, respectively, for
the development of RA and are presented as the odds
ratio (OR) with the 95% confidence interval (CI). Rela-
tionships between categorical data (positive vs. negative)
were compared using chi-square analyses. Considering
the study to be explorative, P ≤0.05 was defined as being
statistically significant. Statistical calculations were per-
formed using the SPSS program for Windows, version
21 (IBM SPSS, Chicago, IL, USA).
Results
Levels of survivin and Flt3L in pre-symptomatic individuals,
RA patients and controls
Analyzing the levels of survivin and Flt3L in plasma
samples using a sandwich ELISA method showed that
the concentrations of both survivin and Flt3L differed
significantly between the three groups (P < 0.001 and
P < 0.05, respectively). Survivin was significantly in-
creased in the presymptomatic individuals compared
with the controls (P = 0.003) whilst the levels of Flt3L
(P = 0.21) were similar in presymptomatic individuals
and controls (Figure 1a,b). The concentration of survivin
increased significantly in RA patients compared with the
presymptomatic individuals (Figures 1a and 2). There
was no direct relationship between the levels of survivin
and Flt3L and the time interval before the onset of the
disease. However, the time interval for the presymptom-
atic individuals positive for survivin was closer to symp-
tom onset compared with survivin-negative individualsFigure 1 Concentrations of survivin and Fms-like tyrosine kinase 3 lig
(a) Survivin concentration in controls (n = 155), presymptomatic individual
significant Kruskal–Wallis test was found between the three groups (P < 0.0
two groups. ***P < 0.001, **P < 0.01 and *P < 0.05. (b) Fms-like tyrosine kin
presymptomatic individuals (n = 47) and patients with RA (n = 36). A signif
(P < 0.05). The Mann–Whitney U test was used for comparisons between tw(median (interquartile range), 1.36 (2.0) years and 4.10
(5.86) years, respectively, P = 0.012). The levels of survi-
vin and Flt3L were significantly increased in RA patients
compared with controls (P < 0.0001 and P = 0.005,
respectively) (Figure 1a,b).
Frequencies of survivin and Flt3L in presymptomatic
individuals, RA patients and controls
The frequencies of survivin and Flt3L above respective
cutoff values in controls, presymptomatic individuals and
RA patients are presented in Table 2. The frequency of
survivin in the presymptomatic individuals was signi
ficantly higher compared with controls (36.2% vs. 14.2%,
P = 0.001). The OR for predicting disease in the presymp-
tomatic individuals compared with controls was 3.4 (95%
CI = 1.6 to 7.2) for survivin. The difference in theand measured by enzyme-linked immunosorbent assay.
s (n = 47) and patients with rheumatoid arthritis (RA; n = 36). A
01). The Mann–Whitney U test was used for comparisons between
ase 3 ligand (Flt3L) concentration in controls (n = 155),
icant Kruskal–Wallis test was found between the three groups
o groups, **P < 0.01. n.s, not significant.
Table 2 Sensitivity (%) and specificity (%) for presymptomatic individuals and rheumatoid arthritis patients. Odds ratio
with 95% confidence interval, PPV and NPV calculated for presymptomatic individuals
RA patients (%) Pre RA (%) Specificity (%) ORa 95% CIa P valuea PPV (%) NPV (%)
Survivin 63.9 36.2 88.3 3.43 1.62-7.23 0.0008 43.6 81.6
Flt3L 33.3 6.4 95.5 1.43 0.36-5.77 0.61374 30.0 77.1
CI, confidence interval; Flt3L, Fms-like tyrosine kinase 3 ligand; NPV, negative predictive value calculated for the presymptomatic individuals; OR, odds ratio;
PPV, positive predictive value calculated for the presymptomatic individuals; RA, rheumatoid arthritis. aCalculated for presymptomatic individuals compared
with controls.
Table 3 Correlations between the concentrations of
Survivin and a cytokine/chemokine









Presented in descending order after Spearman correlation in presymptomatic
individuals. Only cytokines that remained significant after multiple testing are
presented. GM-CSF, granulocyte–macrophage colony-stimulating factor;
MCP-1, monocyte chemoattractant protein-1. *P < 0.05, **P < 0.01 and
***P < 0.001 after adjustments for multiple comparisons.
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found to be significant for both survivin and Flt3L (P <
0.0001, Pearson chi-square) with an OR of 12.1 (95% CI =
5.3 to 27.6) and 11.0 (95% CI = 3.9 to 30.9), respectively,
for predicting disease.
Levels and frequency of survivin and Flt3L in relation to
anti-CCP antibodies
Both presymptomatic individuals and RA patients who
were positive for anti-CCP antibodies had higher levels of
survivin (respectively P = 0.023 and P = 0.021, Mann–
Whitney U test) when compared with anti-CCP negative
individuals.
Among presymptomatic individuals the frequency of
anti-CCP was 25.5%. There was a significant relationship
between the level of survivin above the cutoff value (that
is, being positive) and the presence of anti-CCP anti-
bodies, 66.7% versus 33.3% below the cutoff value for sur-
vivin (χ2 = 6.49, P = 0.016). In multiple regression analysis
including anti-CCP antibodies and survivin, the positivity
for survivin remained a borderline significant predictor for
disease development (OR = 2.26, 95% CI = 0.96 to 5.32,
P = 0.061). In RA patients expressing anti-CCP antibodies,
85.0% had a level of survivin above the cutoff value com-
pared with 15.0% being survivin-negative (χ2 = 5.62, P =
0.026).
There were no significant relationships between Flt3L
concentration or positivity and presence of anti-CCP
antibodies.
Levels of survivin and Flt3L in relation to levels of
cytokines/cytokine receptors and chemokines
The levels of survivin and Flt3L displayed significant
correlation with a number of cytokines and/or chemokines
analyzed in the samples from presymptomatic individuals
and patients with RA. After correction for the number of
comparisons, the levels of both survivin and Flt3L in the
presymptomatic individuals correlated with the levels of
IL-2, IL-9 and IL-12 (Table 3). For survivin, the pattern of
correlations differed between the presymptomatic individ-
uals and the RA patients. In the presymptomatic individ-
uals, survivin correlated with more cytokines (IL-9, IL-12,
IL-1β, IL-2, granulocyte–macrophage colony-stimulating
factor) and these correlations were at a higher significance
level. In the presymptomatic individuals, survivin wasassociated with the cytokines regulating formation of ef-
fector T cells (IL-2) with the major difference occurring in
IL-9 and IL-12; that is, the cytokines predisposing and as-
suring formation of T-helper type (Th) 1 and Th17 proin-
flammatory T-cell subsets. After correcting for the number
of comparisons, the positivity for survivin was only related
to increased concentration of IL-9 (data not shown, P <
0.05). In RA patients, the correlations with survivin were
changed from the regulatory cytokines to the proinflam-
matory cytokines produced by established Th subsets and
to angiogenic factors; that is, interferon-gamma, tumor
necrosis factor alpha, vascular endothelial growth factor
and platelet-derived growth factor BB.
The association between the cytokine/chemokine panel
and Flt3L was different from that of survivin. Flt3L in
presymptomatic individuals was associated with a broader
cytokine pattern (Table 4) that became even broader after
the onset of disease. The statistical associations found be-
tween cytokines and Flt3L in the presymptomatic individ-
uals become stronger in the RA patients and remained
significant after correction for multiple comparisons
(Table 4). In RA patients, the positivity for Flt3L was as-
sociated with IL-13, IL-1β, granulocyte–macrophage
colony-stimulating factor, IL-1 receptor agonist, IL-6, and
IL-9 (P < 0.01 for all) and with IL-2 and IL-10 (P < 0.05 for
both) after corrections for multiple comparisons. No asso-
ciation of positivity for Flt3L and cytokines/chemokines
Table 4 Correlations between the concentrations of Flt3L
and a cytokine/chemokine














Presented in descending order after Spearman Correlation in presymptomatic
individuals. Only cytokines that remained significant after multiple testing are
presented. IL-1Ra, interleukin-1 receptor antagonist; GM-CSF, granulocyte–
macrophage colony-stimulating factor; MCP-1, monocyte chemoattractant
protein-1; MIG, monokine induced by interferon-gamma; TNFα, tumor necrosis
factor alpha. *P < 0.05, **P < 0.01 and ***P < 0.001 after adjustments for
multiple comparisons.
Bokarewa et al. Arthritis Research & Therapy 2014, 16:R45 Page 5 of 7
http://arthritis-research.com/content/16/1/R45remained significant in the presymptomatic individuals
(data not shown).
Discussion
In this pilot study we investigated the presence of survivin
and Flt3L in plasma samples from presymptomatic individ-
uals, population controls and RA patients collected at the
time of diagnosis. Survivin and Flt3L have recently emerged
as biomarkers of joint damage and poor response to anti-
rheumatic treatment [17,18]. The present study addressed
the question of whether the levels of these proteins were
altered before the onset of RA symptoms, and whether they
were associated with other inflammatory markers; for
example, cytokines, chemokines and anti-CCP2 antibodies
analyzed at the same time points. The levels of survivin in
the samples collected years before onset of RA symptoms
were significantly increased compared with matched con-
trols. The levels of survivin were prominently high in the
anti-CCP-positive presymptomatic individuals. In the these
individuals, survivin was most strongly associated with IL-9
and IL-12 (that is, the cytokines predisposing and assuring
formation of Th1 and Th17 proinflammatory T-cell sub-
sets) and also IL-2, the cytokine regulating the formation of
effector T cells. The concentration of Flt3L was most evi-
dently increased in RA patients and to a lower extent in the
presymptomatic individuals. In RA patients, the levels of
Flt3L correlated to the cytokines of the Th1, Th2 and regu-
latory T-cell lineages and monocyte chemoattractant
protein-1, known among the major chemoattractants
produced by the inflamed synovia.Survivin has been shown to be crucial at the early stages
of T-cell development, where it is required for the forma-
tion of a functional T-cell receptor [19,20]. Survivin is also
suggested important for intracellular transfer of signals
from the co-stimulatory molecules during T-cell activation
[21], and for the formation of memory immune responses
[22]. In the context of arthritis, extracellular survivin has
been found in the blood and synovial fluid of RA patients
[11,23]. The proportion of survivin-positive patients varied
between 60% in patients with early RA and 28% in a co-
hort of established and treated RA patients [11,13]. A pro-
spective study of the Swedish patient cohort with early RA
showed that high levels of survivin measured at the first
visit to a rheumatologist were predictive for a severe cause
of the disease [13]. Indeed, extracellular survivin was con-
sistently associated with the development and progression
of joint damage in RA and also distinguished patients with
a therapy-resistant disease, nonresponders to biological
treatment and those with a low rate of disease remission
[11,13,18,23]. High levels of survivin were also detected in
the rheumatoid synovia where the expression of survivin
correlated with the synovial infiltration with macrophages
and memory T cells and with the low rate of apoptosis.
These findings suggested a key function for survivin in the
regulation of invasive properties of fibroblasts in the in-
flamed rheumatic joint [24-26]. The result of our study is
not consistent with these findings, since the concentration
of survivin was increased before the patients presented
any symptoms of joint disease. Of course, we cannot rule
out early synovitis in symptomless individuals, although
results from other studies show a rather late involvement
of the synovia in the antibody-positive patients with joint
complains [27].
The functional effects of Flt3L are mediated and occur
through interaction with Fms-like tyrosine kinase 3, its re-
ceptor tyrosine kinase. Fms-like tyrosine kinase 3/Flt3L sig-
naling has recently been shown critical for the development
of early B-cell progenitors and dendritic cells, and for the
expansion of induced regulatory T cells [10,28]. Blockade of
Flt3L signaling using a small-molecule Fms-like tyrosine
kinase 3 inhibitor ameliorates antigen-induced arthritis
[29]. The experimental analysis of common biological pro-
cesses linked high expression of survivin and Flt3L in RA
patients and showed that Fms-like tyrosine kinase 3/Flt3L
signaling was required for the expression of survivin in vivo
[15]. In this case, the expression of survivin in leukocytes
would appear as a downstream event of Flt3L signaling,
and is in contradiction to the present observation of sur-
vivin as a predictor of disease development. Interestingly,
survivin is increased in the preclinical phase of RA and
showed association with another established predictor of
RA, anti-CCP antibodies. Additionally, survivin was associ-
ated with the pattern of regulatory cytokines (IL-9, IL-12)
already at the presymptomatic stage of RA and potentially
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matory Th1 and Th17 cell subsets with known pathogenic
importance for RA [30,31].
Our recent study showed that the pattern of cytokines
could be helpful in distinguishing presymptomatic individ-
uals from controls or RA patients [5]. In the presymptom-
atic individuals, the RA-specific autoantibody production,
including anti-CCP and IgM-RF, was strongly related to
the T-cell cytokines. These cytokines are essential for the
control of antibody production in the steps of engagement
of antigen-presenting macrophages and B cells (that is,
IL-13 and IL-4 [32]), for the maturation of induced T-
regulatory cells and Th17 cells (that is, IL-9 [30]), and
for the differentiation of follicular B cells and formation
of germinal centers (that is, IL-4 [33]).
There are two major limitations within this study: a
relatively small size of the tested cohort, and a broad
variation of the time interval between the blood samples
collected before the onset of the disease and the RA
diagnosis. These samples were not collected on a regular
basis but were retrieved from the existing bank of blood
donors. Stratification of the studied subjects reduced the
numbers in each group and made additional complica-
tions for the detection of statistical significance.
Conclusions
In summary, increased levels of survivin in patients were
detected years before the onset of RA symptoms, par-
ticularly in those individuals positive for anti-CCP anti-
bodies. The high levels of survivin appear to be more
related to the cytokines produced by the Th1 and Th17
subsets. These results suggest a role for survivin at the
early presymptomatic stages of RA.
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